Literature DB >> 34352377

Bamlivimab + etesevimab therapy induces SARS-COV-2 immune escape mutations and secondary clinical deterioration in Covid-19 patients with B cell malignancies.

F Pommeret1, J Colomba2, C Bigenwald3, A Laparra4, S Bockel5, A Bayle4, J-M Michot4, T Hueso3, L Albiges2, P Tiberghien6, S Marot7, A Jary7, K Lacombe8, F Griscelli9, E Colomba2.   

Abstract

Entities:  

Year:  2021        PMID： 34352377     DOI： 10.1016/j.annonc.2021.07.015

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.

Authors:  N Bansal; M Raturi; Y Bansal
Journal:  Transfus Clin Biol       Date:  2021-12-29       Impact factor: 2.126

2.  Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review.

Authors:  Daniele Focosi; Fabrizio Maggi; Massimo Franchini; Scott McConnell; Arturo Casadevall
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

3.  Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.

Authors:  Aude Jary; Stéphane Marot; Antoine Faycal; Sacha Leon; Sophie Sayon; Karen Zafilaza; Emna Ghidaoui; Stéphanie Nguyen Quoc; Safaa Nemlaghi; Sylvain Choquet; Martin Dres; Valérie Pourcher; Vincent Calvez; Helga Junot; Anne-Geneviève Marcelin; Cathia Soulié
Journal:  Viruses       Date:  2022-01-24       Impact factor: 5.048

4.  XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.

Authors:  Bernard Vanhove; Stéphane Marot; Ray T So; Benjamin Gaborit; Gwénaëlle Evanno; Isabelle Malet; Guillaume Lafrogne; Edwige Mevel; Carine Ciron; Pierre-Joseph Royer; Elsa Lheriteau; François Raffi; Roberto Bruzzone; Chris Ka Pun Mok; Odile Duvaux; Anne-Geneviève Marcelin; Vincent Calvez
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

5.  Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma.

Authors:  David J Sullivan; Kelly A Gebo; Shmuel Shoham; Evan M Bloch; Bryan Lau; Aarthi G Shenoy; Giselle S Mosnaim; Thomas J Gniadek; Yuriko Fukuta; Bela Patel; Sonya L Heath; Adam C Levine; Barry R Meisenberg; Emily S Spivak; Shweta Anjan; Moises A Huaman; Janis E Blair; Judith S Currier; James H Paxton; Jonathan M Gerber; Joann R Petrini; Patrick B Broderick; William Rausch; Marie Elena Cordisco; Jean Hammel; Benjamin Greenblatt; Valerie C Cluzet; Daniel Cruser; Kevin Oei; Matthew Abinante; Laura L Hammitt; Catherine G Sutcliffe; Donald N Forthal; Martin S Zand; Edward R Cachay; Jay S Raval; Seble G Kassaye; E Colin Foster; Michael Roth; Christi E Marshall; Anusha Yarava; Karen Lane; Nichol A McBee; Amy L Gawad; Nicky Karlen; Atika Singh; Daniel E Ford; Douglas A Jabs; Lawrence J Appel; David M Shade; Stephan Ehrhardt; Sheriza N Baksh; Oliver Laeyendecker; Andrew Pekosz; Sabra L Klein; Arturo Casadevall; Aaron A R Tobian; Daniel F Hanley
Journal:  medRxiv       Date:  2021-12-21

6.  De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients.

Authors:  Lacy M Simons; Egon A Ozer; Stephanie Gambut; Taylor J Dean; Li Zhang; Pavan Bhimalli; Jeffrey R Schneider; João I Mamede; Michael G Ison; Reem Karmali; Leo I Gordon; Ramon Lorenzo-Redondo; Judd F Hultquist
Journal:  Transpl Infect Dis       Date:  2022-07-28

Review 7.  COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.

Authors:  Daniele Focosi; Massimo Franchini; Liise-Anne Pirofski; Thierry Burnouf; Nigel Paneth; Michael J Joyner; Arturo Casadevall
Journal:  Clin Microbiol Rev       Date:  2022-03-09       Impact factor: 50.129

8.  Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab.

Authors:  Laura Ballotta; Omar Simonetti; Pierlanfranco D'Agaro; Ludovica Segat; Raffaella Koncan; Pamela Martinez-Orellana; Federica Dattola; Emanuele Orsini; Alessandro Marcello; Simeone Dal Monego; Danilo Licastro; Andrea Misin; Sara Mohamed; Eugenio Sbisà; Elisa Lucchini; Giovanni Maria De Sabbata; Francesco Zaja; Roberto Luzzati
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

Review 9.  The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.

Authors:  Daniele Focosi; Scott McConnell; Arturo Casadevall
Journal:  Drug Resist Updat       Date:  2022-10-03       Impact factor: 22.841
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.